Postdoctoral scholars develop a myriad of skills throughout their work by the very nature of scientific training. Some of these skills include research techniques, experimental design, and data analysis in addition to other, less technical skills. Yet many postdocs struggle first to recognize those skills, and then to articulate them effectively to potential employers. To identify their skills, it is critical for postdocs to start by engaging in self-reflection. Once skills are identified, postdocs need to understand what employers are seeking in job candidates and translate their skills into language that resonates with employers. This article will take a hands-on approach to both tasks: assisting postdocs with conducting a self-assessment to identify their skills and helping them to deconstruct sample job descriptions to become more familiar with the language of industry. Through this process, postdocs will learn how to translate their work in ways that are meaningful to employers, and that address needs that they face. The combination of self-reflection, identifying transferable skills, and then translating these skills to demonstrate value to potential employers, should lead to increased confidence as well as success in navigating the current job market.
As metabolic etiologies become increasingly important in hepatocellular carcinoma (HCC), the causal roles of specific adipose depots independent of overall body size remain unclear. This study used Mendelian randomization (MR) to investigate the associations of MRI-derived fat-depot phenotypes with HCC and to explore potential mediation by plasma lipids. GWAS summary statistics for BMI- and height-adjusted fat-depot phenotypes were obtained from the UK Biobank, and HCC summary statistics were obtained from FinnGen, with replication in the Million Veteran Program. Univariable and multivariable MR were used to estimate total and independent effects, including analyses adjusted for smoking, alcohol consumption, type 2 diabetes, and childhood BMI. A two-step MR framework was applied to assess mediation by 179 plasma lipid species. Genetically predicted gluteofemoral adipose tissue adjusted for BMI and height (GFATadj) was associated with a lower risk of HCC (OR = 0.444, P = 1.00 × 10-4). This association remained robust after adjustment for other risk factors, and it was replicated in the Million Veteran Program (OR = 0.766). Mediation analysis identified six lipid species as potential partial mediators, each accounting for an estimated 7.0%–15.4% of the protective total effect, and colocalization provided only limited support for shared causal variants. Our results provide insight into depot-specific adiposity and lipid metabolic pathways in hepatocarcinogenesis, although further validation is needed to confirm the underlying causal mechanisms.
SEL1L (suppressor/enhancer of lin-12-like) is an endoplasmic reticulum (ER) transmembrane protein that serves as a key regulatory molecule in the endoplasmic reticulum-associated degradation (ERAD) pathway, playing a central role in maintaining intracellular protein homeostasis. This paper provides a systematic review of SEL1L’s structural characteristics, the molecular mechanisms by which it forms a functional complex with the E3 ubiquitin ligase HMG-CoA reductase degradation protein 1 (HRD1, encoded by SYVN1) to synergistically execute ERAD, and its pathophysiological significance in the onset and progression of various diseases. Research indicates that SEL1L dysfunction is closely associated with pathogenic protein aggregation in neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis), protein homeostasis imbalances during tumorigenesis, cellular metabolic dysregulation in metabolic disorders (e.g., diabetes, lipid metabolism disorders), and immune system dysfunction. Furthermore, the expression levels or variants of SEL1L exhibit specific alterations across different tumor tissues, suggesting its potential as a disease biomarker and therapeutic target. This paper aims to synthesize existing research, elucidate the ‘gatekeeper’ role of SEL1L in multiple physiological and pathological processes, and explore the prospects for developing novel therapeutic strategies by targeting the SEL1L-HRD1 complex and related pathways.
Primary frozen shoulder is driven by capsular inflammation followed by progressive fibrosis. Current conservative treatments target inflammation alone and do not address the fibrosis that sustains the loss of motion. Since colchicine has both anti-inflammatory and antifibrotic activity, we tested whether oral colchicine limits inflammation, fibrosis, and the loss of shoulder motion in a rat immobilization model of frozen shoulder. Sixty female Wistar albino rats aged 8 months were randomly assigned to five groups of 12: a healthy sham group, a 3-week untreated control, a 3-week treatment group, a 6-week untreated control, and a 6-week treatment group. Frozen shoulder was induced by plaster immobilization in all groups except the sham group. The treated animals received 0.6 mg of oral colchicine daily by gavage, which is approximately equivalent to 2.2 mg/kg/day. Abduction and external rotation were measured radiographically on harvested specimens, and the joint capsule was graded histopathologically for synovial hyperplasia, inflammatory changes, pannus formation, capillary vessel formation, and connective tissue formation. At 6 weeks, the mean abduction angle was greater in the treatment group than in the matched control (109.6° versus 88.1°), as was the mean external rotation angle (26.8° versus 18.9°), whereas the 3-week groups did not differ significantly in abduction angles. Connective tissue formation was lower in both treatment groups than in their respective controls, and inflammatory changes were reduced at both time points. Immunohistochemistry showed that collagen III was lower in the 3-week treatment group than in its control (2.17 versus 3.50) and collagen I was lower in the 6-week treatment group than in its control (2.50 versus 3.50), a phase-dependent pattern. Differences in synovial hyperplasia, pannus formation, and capillary vessel formation did not reach significance. In this model, colchicine improved shoulder abduction and external rotation and reduced capsular fibrosis and inflammation. Colchicine, already used widely for rheumatologic disease, may have anti-inflammatory and antifibrotic potential in frozen shoulder, although further preclinical and clinical studies are needed before any clinical use. These findings concern the development and progression of capsular fibrosis during continued immobilization; whether colchicine can reverse established contracture was not tested.
Urothelial carcinoma (UC) is a dynamic malignancy characterized by a complex epigenetic landscape. Epigenetic modifications are pivotal in modulating the innate immune response, particularly within the tumor microenvironment (TME), where they profoundly influence natural killer (NK) cell function. Aberrant epigenetic regulation often promotes immune evasion by silencing activating ligands on tumor cells, thereby impairing NK cell-mediated cytotoxicity. Emerging epigenetic therapies, such as histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTis), offer significant potential to reprogram the immune landscape and restore anti-tumor immunity. Despite this promise, clinical implementation faces challenges, including the immunosuppressive nature of the TME, NK cell exhaustion, and complex manufacturing limitations. Combining epigenetic agents with NK cell-based immunotherapies represents a robust strategy to overcome these barriers and improve therapeutic outcomes. This review elucidates the epigenetic regulatory mechanisms in UC and emphasizes the necessity of personalized, biomarker-driven treatment strategies to optimize cancer immunotherapy outcomes.
